Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) has launched Gelclair, an FDA-approved oral mucositis prescription product, in the U.S. This marks Jaguar's third commercialized prescription product and initiates its commercial footprint in cancer supportive care. Gelclair is a gel that adheres to the mouth's mucosal surface, providing rapid and long-lasting pain relief without stinging or numbing.

Oral mucositis, affecting up to 90% of head and neck cancer patients treated with chemotherapy and radiotherapy, is a significant adverse event in oncology. It can lead to treatment interruptions and hospitalization. Jaguar's launch strategy includes a dedicated team of representatives and plans to exhibit at key oncology conferences.

Jaguar Health (NASDAQ:JAGX) has announced new employee inducement grants under Nasdaq Listing Rule 5635(c)(4). Effective October 7, 2024, the company granted restricted stock units (RSUs) to five new employees. New Employee 1 received 80,000 RSUs, which will vest equally over three years, with one-third of the shares vesting each year from the date of hire. New Employees 2-5 each received 15,000 RSUs, which will vest over one year from their respective hire dates.

These RSU grants were approved by Jaguar's Compensation Committee as an inducement for the employees to accept employment with the company. The vesting of the RSUs is contingent on each new employee's continued service with Jaguar through the applicable vesting dates.

Magdalena Biosciences, a joint venture between Jaguar Health and Filament Health, is set to present at the BIO Investor Forum on October 16, 2024. Dr. Karen Brunke, Jaguar's EVP and Acting CEO of Magdalena, will provide an overview of the company's progress in developing novel, natural prescription medicines for mental health indications.

Magdalena's lead botanical drug candidate, MB2500, is expected to be IND-enabled soon for attention deficit hyperactivity disorder (ADHD) and potentially for cognitive deficit in schizophrenia. The company aims to submit an Investigational New Drug (IND) application to the FDA in early 2025, with 1-2 additional IND applications planned for the same year.

MB2500 is derived from a well-characterized plant with neuroprotective and cognitive enhancing properties. Magdalena is focusing on advancing plant-based innovations for mental health conditions, targeting the $25 billion global ADHD market and the growing schizophrenia market, projected to reach $13.41 billion by 2032.

Jaguar Health (NASDAQ:JAGX) has submitted a late-breaking abstract for a first-of-kind study evaluating the impact of diarrhea from cancer therapies in breast cancer patients who received placebo in its OnTarget Phase 3 trial. The study analyzed data from 142 patients with solid tumors, including nearly 75 breast cancer patients receiving targeted therapies with or without standard chemotherapy.

The abstract focuses on the incidence, severity, and management of cancer therapy-related diarrhea (CTD) based on patient-reported outcomes (PROs) collected through digital applications. This marks the first time that the natural history of gastrointestinal symptoms from targeted therapies and/or chemotherapy has been reported directly by patients throughout a CTD study.

Napo Pharmaceuticals, a Jaguar family company, is continuing to analyze data from the OnTarget trial and plans further discussions with the FDA. The study aims to provide insights into cancer therapy dose modifications necessitated by CTD and emphasizes the importance of patient-centric studies in providing appropriate supportive care for adult patients with solid tumors.

Jaguar Health (NASDAQ:JAGX) has reported statistically significant improvement in breast cancer patients in its Phase 3 OnTarget trial for crofelemer, a cancer supportive care drug. The trial evaluated crofelemer for prophylaxis of cancer therapy-related diarrhea. Breast cancer patients accounted for nearly 180 of the 287 participants in this prophylactic clinical trial.

While the initial top line results did not meet the primary estimand for all tumor types, the subgroup analysis in adult breast cancer patients showed clinically meaningful improvement. This suggests crofelemer's potential to help breast cancer patients better adhere to their cancer therapies. The results have been submitted to a relevant oncology conference, and a full study report is expected to be submitted to a peer-reviewed journal.

Additionally, crofelemer has shown benefit in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with results to be presented at the upcoming American College of Gastroenterology Annual Scientific Meeting.

Jaguar Health, Inc. (NASDAQ:JAGX) announced that Stacey Tinianov, MPH, a member of Jaguar's Scientific Advisory Board, will present a poster at the American Society of Clinical Oncology (ASCO) Quality Care Symposium on September 27, 2024. The presentation, titled 'Measuring what really matters: Advocacy-led co-creation and accrual of a pan-cancer QoL survey,' will discuss the methodologies used in designing the 'More Than a Diagnosis' quality of life survey for cancer patients and survivors.

The survey, sponsored by Jaguar's family company Napo Pharmaceuticals, aims to address the limitations of commonly used tools in assessing cancer patients' quality of life concerns. Tinianov emphasized that while cancer treatments have advanced, significant side effects can still impact patients' quality of life. The presentation will highlight the importance of understanding patients' priorities to improve supportive care and effectively address quality of life impacts.

Jaguar Health, Inc. (NASDAQ:JAGX) has announced its participation in the Lytham Partners Fall 2024 Investor Conference, scheduled for October 1, 2024. The virtual event will feature a webcasted presentation by Lisa Conte, the company's founder, president, and CEO, at 1:15pm Eastern. Investors can access the webcast through a provided link, with a replay available after the event.

In addition to the presentation, Jaguar Health's management team will be available for one-on-one virtual meetings with investors throughout the conference. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event through the provided link.

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, will exhibit Gelclair, an FDA-approved oral mucositis prescription product, at the American Society for Radiation Oncology (ASTRO) Annual Meeting from September 29 to October 2, 2024, in Washington, DC. Jaguar plans to launch Gelclair commercially in the U.S. in October 2024.

Gelclair is a protective gel that manages pain by adhering to the mouth's mucosal surface, providing relief for oral lesions, including those caused by oral mucositis/stomatitis. Unlike other products, it doesn't numb or sting the mouth. Oral mucositis, also known as "chemo mouth," affects up to 40% of chemotherapy patients and 90% of head and neck cancer patients treated with chemotherapy and radiotherapy. It can lead to hospitalization, treatment delays, and increased management costs.

The economic impact is significant, with a study showing that severe mucositis/pharyngitis in head and neck cancer patients can result in incremental costs exceeding $17,244 per patient. Jaguar aims to raise awareness among oncologists about Gelclair and its expanding focus on cancer supportive care at the ASTRO Annual Meeting.

Jaguar Health (NASDAQ:JAGX) has announced that its founder, president, and CEO, Lisa Conte, will present at the MedInvest Biotech & Pharma Investor Conference on September 19, 2024, in New York City. The presentation is scheduled for 9:55 AM to 10:10 AM Eastern time. Conte will also participate in one-on-one meetings during the event, which runs from September 18-19.

This conference provides Jaguar Health with an opportunity to showcase its developments and connect with potential investors in the biotech and pharmaceutical sectors. Interested parties can register for the presentation through a provided link, allowing them to gain insights into Jaguar Health's current projects and future prospects.